筋痛性脳脊髄炎/慢性疲労症候群（ME/CFS）におけるリツキシマブの有効性と安全性に関する研究

基本情報

NCT ID

NCT06952413

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

30

治験依頼者名

National Center of Neurology and Psychiatry, Japan

概要

The efficacy and safety of rituximab on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituximab in the primary evaluation period will receive placebo, and the timing and duration of rituximab's effect will be explored throughout the entire evaluation period. Subjects who received placebo during the primary evaluation period will receive rituximab during the secondary evaluation period to explore changes in endpoints before and after switching from placebo to rituximab in the same subjects.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)